

# Maximizing Uptake of Breakthrough Medicines across Canada: Lessons from CAR-T Therapy

Thursday, June 1, 2023



# Housekeeping



## Questions

Submit a question using the Q&A function at any time



## Slides

The slides and a webinar recording will be sent via email



## Survey

Please take a few minutes to complete the survey that will be sent to attendees this afternoon



I2U – or Idea to Utilization –  
is an initiative to offer health system leaders across  
Canada the **knowledge, support and information**  
they need to be better prepared to capture the full  
value of future breakthrough medicines that  
emerge from world-class biomedical research.



**I2U's Focus: Maximizing the  
Value of Breakthrough Drugs  
after reimbursement decisions  
have been made**

# Our Advisory Board



**Dr. Shaan Chugh**  
Medical Director of Solutions,  
Trillium Health Partners



**Martine Elias**  
Executive Director,  
Myeloma Canada



**Zayna Khayat**  
VP of Client Success &  
Growth, Teledoc Health



**Marcel Saulnier**  
Associate, Santis Health;  
Former ADM, Health  
Canada



**Graham Statt**  
Former ADM, Alberta Ministry of  
Health and Vice-Chair, pCPA



**Helen Stevenson**  
Founder and CEO,  
Reformulary Group



**Dr. Robyn Tamblyn**  
Professor of Medicine and  
Medical Scientist, McGill  
University

# Today's Panelists



**Marcel Saulnier**

Associate, Santis  
Health; Former  
ADM, Health  
Canada



**Martine Elias**

Executive Director,  
Myeloma Canada



**Graham Statt**

Former ADM,  
Alberta Ministry of  
Health and Vice-  
Chair, pCPA



**Caroline Barber**

Vice-President of Public  
Affairs and Government  
Relations, Novartis  
Canada

# Case Studies: Identifying Key Barriers to Implementation



## CAR-T THERAPY

A Retrospective Case Study on a Novel Immunotherapy



## LUXTURNA

A Retrospective Case Study on a Specialized Gene Therapy



## LEQEMBI

A Prospective Case Study on a New Alzheimer's Drug

# **Current Context on CAR-T Therapy in Canada**




# Background

- CAR-T Therapy is a **type of cell therapy** that provides a **personalized, target treatment** to fight cancer.
- There are currently **several commercially available CAR-T therapies for blood cancer indications** that have been approved in Canada.
- Given the highly personalized nature of CAR-T Therapy, this class of medicines **cannot be delivered through traditional community-based pharmacies** and instead **requires significant infrastructure and expertise** for administration of treatment.

ACCESS IN CANADA

# Access to Commercial CAR-T Therapies



# Implementation Challenges in Canada



**1. The Need for Administrative Infrastructure:** CAR-T Therapy requires accredited sites with institution-accredited staff with expertise in its delivery.

**2. Manufacturing Capabilities of CAR-T Cells:** There is further development required for in-house manufacturing before there is widespread access across Canada.

# Implementation Challenges in Canada



**3. Need for Cold Chain Management Infrastructure:** CAR-T cells must be cryopreserved starting from manufacturing facilities, during transport and at treatment centres.

**4. Capacity for Post-Infusion Care:** There is a need for capacity for potential in-patient admission after patients receive treatment.

# Learn More About I2U



**[www.i2u.ca](http://www.i2u.ca)**



**I2U**



Accelerating the Journey  
from Idea to Utilization